{"protocolSection":{"identificationModule":{"nctId":"NCT01182441","orgStudyIdInfo":{"id":"CT1004"},"organization":{"fullName":"Boston Scientific Corporation","class":"INDUSTRY"},"briefTitle":"Evaluation of the WATCHMAN Left Atrial Appendage (LAA) Closure Device in Patients With Atrial Fibrillation Versus Long Term Warfarin Therapy","officialTitle":"Prospective Randomized Evaluation of the WATCHMAN LAA Closure Device in Patients With Atrial Fibrillation (AF) Versus Long Term Warfarin Therapy","acronym":"PREVAIL"},"statusModule":{"statusVerifiedDate":"2017-03","overallStatus":"COMPLETED","expandedAccessInfo":{"hasExpandedAccess":false},"startDateStruct":{"date":"2010-11","type":"ACTUAL"},"primaryCompletionDateStruct":{"date":"2013-01","type":"ACTUAL"},"completionDateStruct":{"date":"2017-11","type":"ACTUAL"},"studyFirstSubmitDate":"2010-08-12","studyFirstSubmitQcDate":"2010-08-12","studyFirstPostDateStruct":{"date":"2010-08-16","type":"ESTIMATED"},"resultsFirstSubmitDate":"2017-04-03","resultsFirstSubmitQcDate":"2018-07-25","resultsFirstPostDateStruct":{"date":"2018-07-26","type":"ACTUAL"},"lastUpdateSubmitDate":"2018-07-25","lastUpdatePostDateStruct":{"date":"2018-07-26","type":"ACTUAL"}},"sponsorCollaboratorsModule":{"responsibleParty":{"type":"SPONSOR"},"leadSponsor":{"name":"Boston Scientific Corporation","class":"INDUSTRY"}},"oversightModule":{"oversightHasDmc":true},"descriptionModule":{"briefSummary":"This was a prospective, randomized, multicenter study to provide additional information on the safety and efficacy of the WATCHMAN LAA Closure Technology. The purpose of the PREVAIL study was to confirm the efficacy endpoint as demonstrated in the PROTECT AF pivotal study and to further demonstrate that the WATCHMAN LAA Closure Technology is safe and effective in subjects with non-valvular atrial fibrillation who require anticoagulation therapy for potential thrombus formation."},"conditionsModule":{"conditions":["Atrial Fibrillation","Stroke"],"keywords":["atrial fibrillation","stroke","TIA","trans ischemic attack","warfarin","Coumadin"]},"designModule":{"studyType":"INTERVENTIONAL","phases":["PHASE3"],"designInfo":{"allocation":"RANDOMIZED","interventionModel":"PARALLEL","primaryPurpose":"TREATMENT","maskingInfo":{"masking":"NONE"}},"enrollmentInfo":{"count":407,"type":"ACTUAL"}},"armsInterventionsModule":{"armGroups":[{"label":"WATCHMAN","type":"EXPERIMENTAL","description":"Subjects assigned to receive the WATCHMAN device.","interventionNames":["Device: WATCHMAN Device"]},{"label":"Warfarin","type":"ACTIVE_COMPARATOR","description":"Subjects assigned to warfarin therapy.","interventionNames":["Drug: Warfarin"]}],"interventions":[{"type":"DEVICE","name":"WATCHMAN Device","description":"WATCHMAN Left Atrial Appendage Closure Technology","armGroupLabels":["WATCHMAN"]},{"type":"DRUG","name":"Warfarin","description":"Warfarin dosage prescribed by study physician to adequately maintain an INR of 2.0-3.0","armGroupLabels":["Warfarin"],"otherNames":["Coumadin"]}]},"outcomesModule":{"primaryOutcomes":[{"measure":"Primary Safety Endpoint (Device Group Only)","description":"7-Day procedure rate of death, ischemic stroke, systemic embolism and complications requiring major cardiovascular or endovascular intervention.","timeFrame":"7-Day"},{"measure":"Composite of Stroke, Systemic Embolism, and Death (Cardiovascular and Unknown)","description":"The endpoint was analyzed using a Bayesian piecewise exponential model with the historical priors based on data from the previous pivotal study PROTECT AF. This was a non-inferiority design with comparison of rate ratio of 18-month event rates of the Device and Control groups. The 18-month rate represents the probability of an event occurring within 18 months, and the 18-month rate ratio is a mean of the rate ratios. The primary endpoint was based on a calculation of the probability of events at 18 months but the statistical piecewise hazards model does not require the observation of any subjects out to 18-months.","timeFrame":"18 month rate"},{"measure":"Composite of Ischemic Stroke or Systemic Embolism","description":"Composite of ischemic stroke or systemic embolism excluding events that occurred in the first 7 days following randomization","timeFrame":"Day 8 to 18-months"}]},"eligibilityModule":{"eligibilityCriteria":"Key Inclusion Criteria:\n\n* Paroxysmal, persistent or permanent non-valvular AF\n* Eligible for long-term warfarin therapy\n* Eligible to come off warfarin therapy\n* Calculated CHADS2 score of 2 or greater. Also patients with a CHADS2 score of 1 may be included if any of the following apply:\n\n  * Female age 75 or older\n  * Baseline LVEF â‰¥ 30 and \\< 35%\n  * Aged 65-74 and has diabetes or coronary artery disease\n  * Aged 65 or greater and has congestive heart failure\n\nKey Exclusion Criteria:\n\n* Contraindicated/allergic to aspirin\n* Indicated for clopidogrel therapy or has taken clopidogrel within 7 days prior to enrollment\n* History of atrial septal repair or has an ASD/PFO device\n* Implanted mechanical valve prosthesis\n* NYHA Class IV CHF\n* Resting heart rate \\> 110 bpm\n* Participated previously in the PROTECT AF or CAP Registry studies\n\nKey Echo Exclusion Criteria:\n\n* LVEF \\< 30%\n* Existing pericardial effusion \\> 2mm\n* High risk PFO\n* Significant mitral valve stenosis\n* Complex atheroma with mobile plaque of the descending aorta and/or aortic arch\n* Cardiac tumor","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"contactsLocationsModule":{"overallOfficials":[{"name":"David R. Holmes, M.D.","affiliation":"Mayo Clinic","role":"PRINCIPAL_INVESTIGATOR"},{"name":"Vivek Y. Reddy, M.D.","affiliation":"Icahn School of Medicine at Mount Sinai","role":"PRINCIPAL_INVESTIGATOR"}],"locations":[{"facility":"Mercy Gilbert Medical Center","city":"Gilbert","state":"Arizona","zip":"85297","country":"United States","geoPoint":{"lat":33.35283,"lon":-111.78903}},{"facility":"Arizona Heart Rhythm Research Center","city":"Scottsdale","state":"Arizona","zip":"85251","country":"United States","geoPoint":{"lat":33.50921,"lon":-111.89903}},{"facility":"Foundation for Cardiovascular Medicine","city":"La Jolla","state":"California","zip":"92037","country":"United States","geoPoint":{"lat":32.84727,"lon":-117.2742}},{"facility":"Scripps Green","city":"La Jolla","state":"California","zip":"92037","country":"United States","geoPoint":{"lat":32.84727,"lon":-117.2742}},{"facility":"Cedars-Sinai Medical Center","city":"Los Angeles","state":"California","zip":"90048","country":"United States","geoPoint":{"lat":34.05223,"lon":-118.24368}},{"facility":"Orange County Heart","city":"Orange","state":"California","zip":"92868","country":"United States","geoPoint":{"lat":33.78779,"lon":-117.85311}},{"facility":"St. John's Hospital / Pacific Heart","city":"Santa Monica","state":"California","zip":"90404","country":"United States","geoPoint":{"lat":34.01945,"lon":-118.49119}},{"facility":"Zasa Clinical Research","city":"Atlantis","state":"Florida","zip":"33462","country":"United States","geoPoint":{"lat":26.5909,"lon":-80.10088}},{"facility":"Baptist Hospital of Miami","city":"Miami","state":"Florida","zip":"33176","country":"United States","geoPoint":{"lat":25.77427,"lon":-80.19366}},{"facility":"Florida Hospital","city":"Orlando","state":"Florida","zip":"32803","country":"United States","geoPoint":{"lat":28.53834,"lon":-81.37924}},{"facility":"Emory University","city":"Atlanta","state":"Georgia","zip":"30308","country":"United States","geoPoint":{"lat":33.749,"lon":-84.38798}},{"facility":"North Shore University","city":"Evanston","state":"Illinois","zip":"60201","country":"United States","geoPoint":{"lat":42.04114,"lon":-87.69006}},{"facility":"Iowa Heart Center","city":"Des Moines","state":"Iowa","zip":"50314","country":"United States","geoPoint":{"lat":41.60054,"lon":-93.60911}},{"facility":"Central Baptist Hospital","city":"Lexington","state":"Kentucky","zip":"40503","country":"United States","geoPoint":{"lat":37.98869,"lon":-84.47772}},{"facility":"Massachusetts General Hospital","city":"Boston","state":"Massachusetts","zip":"02114","country":"United States","geoPoint":{"lat":42.35843,"lon":-71.05977}},{"facility":"Lahey Clinic","city":"Burlington","state":"Massachusetts","zip":"01805","country":"United States","geoPoint":{"lat":42.50482,"lon":-71.19561}},{"facility":"University of Michigan Medical Center","city":"Ann Arbor","state":"Michigan","zip":"48109","country":"United States","geoPoint":{"lat":42.27756,"lon":-83.74088}},{"facility":"William Beaumont","city":"Royal Oak","state":"Michigan","zip":"48073","country":"United States","geoPoint":{"lat":42.48948,"lon":-83.14465}},{"facility":"Abbott Northwestern Hospital","city":"Minneapolis","state":"Minnesota","zip":"55407","country":"United States","geoPoint":{"lat":44.97997,"lon":-93.26384}},{"facility":"Mayo Clinic","city":"Rochester","state":"Minnesota","zip":"55902","country":"United States","geoPoint":{"lat":44.02163,"lon":-92.4699}},{"facility":"Cardiology Associates of N. Mississippi","city":"Tupelo","state":"Mississippi","zip":"38801","country":"United States","geoPoint":{"lat":34.25807,"lon":-88.70464}},{"facility":"St. Luke's Hospital","city":"Kansas City","state":"Missouri","zip":"64111","country":"United States","geoPoint":{"lat":39.09973,"lon":-94.57857}},{"facility":"St. John's Mercy","city":"Saint Louis","state":"Missouri","zip":"63141","country":"United States","geoPoint":{"lat":38.62727,"lon":-90.19789}},{"facility":"Bryan LGH","city":"Lincoln","state":"Nebraska","zip":"68506","country":"United States","geoPoint":{"lat":40.8,"lon":-96.66696}},{"facility":"Englewood Hospital and Medical Center","city":"Englewood","state":"New Jersey","zip":"07631","country":"United States","geoPoint":{"lat":40.89288,"lon":-73.97264}},{"facility":"New York University Medical Center","city":"New York","state":"New York","zip":"10016","country":"United States","geoPoint":{"lat":40.71427,"lon":-74.00597}},{"facility":"Mt. Sinai School of Medicine","city":"New York","state":"New York","zip":"10029","country":"United States","geoPoint":{"lat":40.71427,"lon":-74.00597}},{"facility":"Columbia University Medical Center","city":"New York","state":"New York","zip":"10032","country":"United States","geoPoint":{"lat":40.71427,"lon":-74.00597}},{"facility":"Carolinas Medical Center","city":"Charlotte","state":"North Carolina","zip":"28203","country":"United States","geoPoint":{"lat":35.22709,"lon":-80.84313}},{"facility":"Lindner Clinical Trial Center","city":"Cincinnati","state":"Ohio","zip":"45219","country":"United States","geoPoint":{"lat":39.12713,"lon":-84.51435}},{"facility":"Cleveland Clinic","city":"Cleveland","state":"Ohio","zip":"44195","country":"United States","geoPoint":{"lat":41.4995,"lon":-81.69541}},{"facility":"Hospital of the University of Pennsylvania","city":"Philadelphia","state":"Pennsylvania","zip":"19104","country":"United States","geoPoint":{"lat":39.95233,"lon":-75.16379}},{"facility":"Moffitt Heart & Vascular","city":"Wormleysburg","state":"Pennsylvania","zip":"17043","country":"United States","geoPoint":{"lat":40.26287,"lon":-76.91386}},{"facility":"St. Thomas Research Institute","city":"Nashville","state":"Tennessee","zip":"37203","country":"United States","geoPoint":{"lat":36.16589,"lon":-86.78444}},{"facility":"Texas Cardiac Arrhythmia","city":"Austin","state":"Texas","zip":"78705","country":"United States","geoPoint":{"lat":30.26715,"lon":-97.74306}},{"facility":"Baylor Research Institute","city":"Dallas","state":"Texas","zip":"75226","country":"United States","geoPoint":{"lat":32.78306,"lon":-96.80667}},{"facility":"Methodist Hospital","city":"Houston","state":"Texas","zip":"77030","country":"United States","geoPoint":{"lat":29.76328,"lon":-95.36327}},{"facility":"Intermountain Medical Center","city":"Salt Lake City","state":"Utah","zip":"84107","country":"United States","geoPoint":{"lat":40.76078,"lon":-111.89105}},{"facility":"Fletcher Allen","city":"Burlington","state":"Vermont","zip":"05401","country":"United States","geoPoint":{"lat":44.47588,"lon":-73.21207}},{"facility":"Swedish Medical Center","city":"Seattle","state":"Washington","zip":"98104","country":"United States","geoPoint":{"lat":47.60621,"lon":-122.33207}},{"facility":"St. Luke's Hospital","city":"Milwaukee","state":"Wisconsin","zip":"53215","country":"United States","geoPoint":{"lat":43.0389,"lon":-87.90647}}]},"referencesModule":{"references":[{"pmid":"35902169","type":"DERIVED","citation":"Dukkipati SR, Holmes DR Jr, Doshi SK, Kar S, Singh SM, Gibson D, Price MJ, Natale A, Mansour M, Sievert H, Houle VM, Allocco DJ, Reddy VY. Impact of Peridevice Leak on 5-Year Outcomes After Left Atrial Appendage Closure. J Am Coll Cardiol. 2022 Aug 2;80(5):469-483. doi: 10.1016/j.jacc.2022.04.062."},{"pmid":"35512918","type":"DERIVED","citation":"Friedman DJ, Du C, Wang Y, Agarwal V, Varosy PD, Masoudi FA, Holmes DR, Reddy VY, Price MJ, Curtis JP, Freeman JV. Patient-Level Analysis of Watchman Left Atrial Appendage Occlusion in Practice Versus Clinical Trials. JACC Cardiovasc Interv. 2022 May 9;15(9):950-961. doi: 10.1016/j.jcin.2022.02.029. Erratum In: JACC Cardiovasc Interv. 2022 Aug 22;15(16):1693."},{"pmid":"31752643","type":"DERIVED","citation":"Brouwer TF, Whang W, Kuroki K, Halperin JL, Reddy VY. Net Clinical Benefit of Left Atrial Appendage Closure Versus Warfarin in Patients With Atrial Fibrillation: A Pooled Analysis of the Randomized PROTECT-AF and PREVAIL Studies. J Am Heart Assoc. 2019 Dec 3;8(23):e013525. doi: 10.1161/JAHA.119.013525. Epub 2019 Nov 22."},{"pmid":"26627989","type":"DERIVED","citation":"Price MJ, Reddy VY, Valderrabano M, Halperin JL, Gibson DN, Gordon N, Huber KC, Holmes DR Jr. Bleeding Outcomes After Left Atrial Appendage Closure Compared With Long-Term Warfarin: A Pooled, Patient-Level Analysis of the WATCHMAN Randomized Trial Experience. JACC Cardiovasc Interv. 2015 Dec 28;8(15):1925-1932. doi: 10.1016/j.jcin.2015.08.035. Epub 2015 Nov 25."}]},"ipdSharingStatementModule":{"ipdSharing":"NO"}},"resultsSection":{"participantFlowModule":{"groups":[{"id":"FG000","title":"WATCHMAN","description":"Subjects assigned to receive the WATCHMAN device.\n\nWATCHMAN Device: WATCHMAN Left Atrial Appendage Closure Technology"},{"id":"FG001","title":"Warfarin","description":"Subjects assigned to warfarin therapy.\n\nWarfarin: Warfarin dosage prescribed by study physician to adequately maintain an INR of 2.0-3.0"}],"periods":[{"title":"Overall Study","milestones":[{"type":"STARTED","achievements":[{"groupId":"FG000","numSubjects":"269"},{"groupId":"FG001","numSubjects":"138"}]},{"type":"COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"49"},{"groupId":"FG001","numSubjects":"19"}]},{"type":"NOT COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"220"},{"groupId":"FG001","numSubjects":"119"}]}],"dropWithdraws":[{"type":"Patient Still in Follow-up","reasons":[{"groupId":"FG000","numSubjects":"152"},{"groupId":"FG001","numSubjects":"72"}]},{"type":"Death","reasons":[{"groupId":"FG000","numSubjects":"37"},{"groupId":"FG001","numSubjects":"25"}]},{"type":"Implant Attempt Unsuccessful","reasons":[{"groupId":"FG000","numSubjects":"13"},{"groupId":"FG001","numSubjects":"0"}]},{"type":"Lost to Follow-up","reasons":[{"groupId":"FG000","numSubjects":"5"},{"groupId":"FG001","numSubjects":"8"}]},{"type":"Withdrawal by Subject","reasons":[{"groupId":"FG000","numSubjects":"6"},{"groupId":"FG001","numSubjects":"13"}]},{"type":"Implant Not Attempted","reasons":[{"groupId":"FG000","numSubjects":"4"},{"groupId":"FG001","numSubjects":"0"}]},{"type":"Adverse Event","reasons":[{"groupId":"FG000","numSubjects":"2"},{"groupId":"FG001","numSubjects":"0"}]},{"type":"Physician Decision","reasons":[{"groupId":"FG000","numSubjects":"1"},{"groupId":"FG001","numSubjects":"1"}]}]}]},"baselineCharacteristicsModule":{"groups":[{"id":"BG000","title":"WATCHMAN","description":"Subjects assigned to receive the WATCHMAN device.\n\nWATCHMAN Device: WATCHMAN Left Atrial Appendage Closure Technology"},{"id":"BG001","title":"Warfarin","description":"Subjects assigned to warfarin therapy.\n\nWarfarin: Warfarin dosage prescribed by study physician to adequately maintain an INR of 2.0-3.0"},{"id":"BG002","title":"Total","description":"Total of all reporting groups"}],"denoms":[{"units":"Participants","counts":[{"groupId":"BG000","value":"269"},{"groupId":"BG001","value":"138"},{"groupId":"BG002","value":"407"}]}],"measures":[{"title":"Age, Continuous","paramType":"MEAN","dispersionType":"STANDARD_DEVIATION","unitOfMeasure":"years","classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"74.0","spread":"7.4"},{"groupId":"BG001","value":"74.9","spread":"7.2"},{"groupId":"BG002","value":"74.3","spread":"7.4"}]}]}]},{"title":"Sex: Female, Male","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"categories":[{"title":"Female","measurements":[{"groupId":"BG000","value":"87"},{"groupId":"BG001","value":"35"},{"groupId":"BG002","value":"122"}]},{"title":"Male","measurements":[{"groupId":"BG000","value":"182"},{"groupId":"BG001","value":"103"},{"groupId":"BG002","value":"285"}]}]}]},{"title":"Race/Ethnicity, Customized","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"title":"Asian","categories":[{"measurements":[{"groupId":"BG000","value":"1"},{"groupId":"BG001","value":"1"},{"groupId":"BG002","value":"2"}]}]},{"title":"Black/Aftrican American","categories":[{"measurements":[{"groupId":"BG000","value":"6"},{"groupId":"BG001","value":"1"},{"groupId":"BG002","value":"7"}]}]},{"title":"Caucasian","categories":[{"measurements":[{"groupId":"BG000","value":"253"},{"groupId":"BG001","value":"131"},{"groupId":"BG002","value":"384"}]}]},{"title":"Hispanic/Latino","categories":[{"measurements":[{"groupId":"BG000","value":"6"},{"groupId":"BG001","value":"5"},{"groupId":"BG002","value":"11"}]}]},{"title":"Native American Indian/Alaskan Native","categories":[{"measurements":[{"groupId":"BG000","value":"1"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"1"}]}]},{"title":"Other","categories":[{"measurements":[{"groupId":"BG000","value":"2"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"2"}]}]}]},{"title":"Region of Enrollment","paramType":"NUMBER","unitOfMeasure":"participants","classes":[{"title":"United States","categories":[{"measurements":[{"groupId":"BG000","value":"269"},{"groupId":"BG001","value":"138"},{"groupId":"BG002","value":"407"}]}]}]},{"title":"CHADS2 Stroke Risk Score","description":"The CHADS2 score is used to estimate the risk of stroke in patients with non-rheumatic atrial fibrillation. To calculate the CHADS2 score, one point was assigned each for the presence of Congestive heart failure, history of Hypertension, Age 75 years or older, and Diabetes, and two points assigned for prior Stroke or TIA.\n\nThe range for this stroke scale is 0, with an annual stroke risk of 1.9%, to 6, which represents the highest risk of stroke for these patients using this scale and an annual stroke risk of 18.2% (JAMA. 285 (22): 2864-70).","paramType":"MEAN","dispersionType":"STANDARD_DEVIATION","unitOfMeasure":"scores on a scale","classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"2.6","spread":"1.0"},{"groupId":"BG001","value":"2.6","spread":"1.0"},{"groupId":"BG002","value":"2.6","spread":"1.0"}]}]}]}]},"outcomeMeasuresModule":{"outcomeMeasures":[{"type":"PRIMARY","title":"Primary Safety Endpoint (Device Group Only)","description":"7-Day procedure rate of death, ischemic stroke, systemic embolism and complications requiring major cardiovascular or endovascular intervention.","reportingStatus":"POSTED","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","timeFrame":"7-Day","groups":[{"id":"OG000","title":"WATCHMAN","description":"Subjects assigned to receive the WATCHMAN device.\n\nWATCHMAN Device: WATCHMAN Left Atrial Appendage Closure Technology"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"269"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"6"}]}]}],"analyses":[{"groupIds":["OG000"],"groupDescription":"Bayesian calculations were used to incorporate the data from PROTECT AF CAP Registry through a conjugate beta-binomial model. A one-sided upper 95% credible interval for the event rate was calculated based off this posterior distribution.","nonInferiorityType":"SUPERIORITY","nonInferiorityComment":"Success for this endpoint was achieved if the probability of experiencing an event was statistically less than the performance goal, defined as 2.67%, with an upper bound of the one-sided 95% credible interval less than the performance goal.","paramType":"probability of experiencing an event","paramValue":"2.2","ciPctValue":"95","ciNumSides":"ONE_SIDED","ciUpperLimit":"2.652"}]},{"type":"PRIMARY","title":"Composite of Stroke, Systemic Embolism, and Death (Cardiovascular and Unknown)","description":"The endpoint was analyzed using a Bayesian piecewise exponential model with the historical priors based on data from the previous pivotal study PROTECT AF. This was a non-inferiority design with comparison of rate ratio of 18-month event rates of the Device and Control groups. The 18-month rate represents the probability of an event occurring within 18 months, and the 18-month rate ratio is a mean of the rate ratios. The primary endpoint was based on a calculation of the probability of events at 18 months but the statistical piecewise hazards model does not require the observation of any subjects out to 18-months.","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"Probability of events within 18 months","timeFrame":"18 month rate","groups":[{"id":"OG000","title":"WATCHMAN","description":"Subjects assigned to receive the WATCHMAN device.\n\nWATCHMAN Device: WATCHMAN Left Atrial Appendage Closure Technology"},{"id":"OG001","title":"Warfarin","description":"Subjects assigned to warfarin therapy.\n\nWarfarin: Warfarin dosage prescribed by study physician to adequately maintain an INR of 2.0-3.0"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"269"},{"groupId":"OG001","value":"138"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.064"},{"groupId":"OG001","value":"0.063"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"groupDescription":"A Bayesian piecewise exponential model was used to model the 18-month event rates. Historical priors for each interval model were based on PROTECT AF. Hazards were modeled for 0-7 day, 7-60 day, 60-182 day, and 182+ day intervals. Event rates were estimated separately by treatment group and event type. The posterior distribution for the 18-month event rate ratio (WATCHMAN vs. Warfarin), and the corresponding equitailed 95% credible interval, were determined via Monte Carlo simulations.","nonInferiorityType":"NON_INFERIORITY","nonInferiorityComment":"This endpoint is met if the 95% Credible Interval for the rate ratio of WATCHMAN versus Warfarin is entirely less than 1.75.","paramType":"Risk Ratio (RR)","paramValue":"1.07","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"0.57","ciUpperLimit":"1.89"}]},{"type":"PRIMARY","title":"Composite of Ischemic Stroke or Systemic Embolism","description":"Composite of ischemic stroke or systemic embolism excluding events that occurred in the first 7 days following randomization","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"Probability of events within 18-months","timeFrame":"Day 8 to 18-months","groups":[{"id":"OG000","title":"WATCHMAN","description":"Subjects assigned to receive the WATCHMAN device.\n\nWATCHMAN Device: WATCHMAN Left Atrial Appendage Closure Technology"},{"id":"OG001","title":"Warfarin","description":"Subjects assigned to warfarin therapy.\n\nWarfarin: Warfarin dosage prescribed by study physician to adequately maintain an INR of 2.0-3.0"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"269"},{"groupId":"OG001","value":"138"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.0253"},{"groupId":"OG001","value":"0.0200"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"groupDescription":"A Bayesian piecewise exponential model was used to model the 18-month event rates. Historical priors for each interval were based on PROTECT AF. Hazards were modeled for 0-7 day, 7-60 day, 60-182 day, and 182+ day intervals. Event rates were estimated separately for the WATCHMAN and Warfarin groups. The posterior distribution for the 18-month event rate ratio (WATCHMAN vs. Warfarin), and the corresponding equitailed 95% credible interval, were determined via Monte Carlo simulations.","nonInferiorityType":"NON_INFERIORITY","nonInferiorityComment":"This endpoint is met if either the 95% Credible Interval for the risk ratio \\< 2.0 or the 95% Credible Interval for the risk difference is \\< 0.0275.","paramType":"Risk Difference (RD)","paramValue":"0.0053","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"-0.0190","ciUpperLimit":"0.0273"},{"groupIds":["OG000","OG001"],"groupDescription":"A Bayesian piecewise exponential model was used to model the 18-month event rates. Historical priors for each interval were based on PROTECT AF. Hazards were modeled for 0-7 day, 7-60 day, 60-182 day, and 182+ day intervals. Event rates were estimated separately for the WATCHMAN and Warfarin groups. The posterior distribution for the 18-month event rate ratio (WATCHMAN vs. Warfarin), and the corresponding equitailed 95% credible interval, were determined via Monte Carlo simulations.","nonInferiorityType":"NON_INFERIORITY","nonInferiorityComment":"This endpoint is met if either the 95% Credible Interval for the risk ratio \\< 2.0 or the 95% Credible Interval for the risk difference is \\< 0.0275.","paramType":"Risk Ratio (RR)","paramValue":"1.6","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"0.5","ciUpperLimit":"4.2"}]}]},"adverseEventsModule":{"frequencyThreshold":"0","timeFrame":"Randomization through 5-years","eventGroups":[{"id":"EG000","title":"WATCHMAN","description":"Subjects assigned to receive the WATCHMAN device.\n\nWATCHMAN Device: WATCHMAN Left Atrial Appendage Closure Technology","deathsNumAffected":37,"deathsNumAtRisk":269,"seriousNumAffected":86,"seriousNumAtRisk":269,"otherNumAffected":38,"otherNumAtRisk":269},{"id":"EG001","title":"Warfarin","description":"Subjects assigned to warfarin therapy.\n\nWarfarin: Warfarin dosage prescribed by study physician to adequately maintain an INR of 2.0-3.0","deathsNumAffected":25,"deathsNumAtRisk":138,"seriousNumAffected":44,"seriousNumAtRisk":138,"otherNumAffected":10,"otherNumAtRisk":138}],"seriousEvents":[{"term":"AV fistula","organSystem":"Vascular disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":269},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":138}]},{"term":"Anemia requiring transfusion","organSystem":"Blood and lymphatic system disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":3,"numAtRisk":269},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":138}]},{"term":"Bleeding, other","organSystem":"Blood and lymphatic system disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":269},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":138}]},{"term":"Cardiac perforation","organSystem":"Injury, poisoning and procedural complications","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":269},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":138}]},{"term":"Cranial bleed","organSystem":"General disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":269},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":138}]},{"term":"Death","organSystem":"General disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":36,"numAffected":36,"numAtRisk":269},{"groupId":"EG001","numEvents":24,"numAffected":24,"numAtRisk":138}]},{"term":"Device embolization","organSystem":"Injury, poisoning and procedural complications","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":269},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":138}]},{"term":"Device thrombus","organSystem":"General disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":269},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":138}]},{"term":"Epistaxis","organSystem":"Ear and labyrinth disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":269},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":138}]},{"term":"Gastrointestinal bleeding","organSystem":"Gastrointestinal disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":19,"numAffected":19,"numAtRisk":269},{"groupId":"EG001","numEvents":12,"numAffected":12,"numAtRisk":138}]},{"term":"Hematoma","organSystem":"Blood and lymphatic system disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":269},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":138}]},{"term":"Hematuria","organSystem":"Gastrointestinal disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":269},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":138}]},{"term":"Infection","organSystem":"Infections and infestations","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":3,"numAtRisk":269},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":138}]},{"term":"Major bleeding requiring transfusion","organSystem":"Blood and lymphatic system disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":6,"numAffected":6,"numAtRisk":269},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":138}]},{"term":"Other study related","organSystem":"General disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":7,"numAffected":6,"numAtRisk":269},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":138}]},{"term":"Pericardial effusion with cardiac tamponade","organSystem":"Injury, poisoning and procedural complications","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":4,"numAffected":4,"numAtRisk":269},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":138}]},{"term":"Pseudoaneurysm","organSystem":"Vascular disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":269},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":138}]},{"term":"Rectal bleeding","organSystem":"Gastrointestinal disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":269},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":138}]},{"term":"Respiratory failure","organSystem":"Respiratory, thoracic and mediastinal disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":269},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":138}]},{"term":"Respiratory insufficiency","organSystem":"Respiratory, thoracic and mediastinal disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":269},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":138}]},{"term":"Hemorrhagic stroke","organSystem":"Cardiac disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":269},{"groupId":"EG001","numEvents":3,"numAffected":3,"numAtRisk":138}]},{"term":"Ischemic stroke","organSystem":"Cardiac disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":16,"numAffected":15,"numAtRisk":269},{"groupId":"EG001","numEvents":4,"numAffected":4,"numAtRisk":138}]},{"term":"Subdural hematoma","organSystem":"Blood and lymphatic system disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":269},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":138}]},{"term":"Systemic embolism","organSystem":"Cardiac disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":269},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":138}]},{"term":"Transient ischemic attack","organSystem":"Cardiac disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":6,"numAffected":5,"numAtRisk":269},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":138}]}],"otherEvents":[{"term":"Anemia requiring transfusion","organSystem":"Blood and lymphatic system disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":5,"numAffected":4,"numAtRisk":269},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":138}]},{"term":"Bleeding, other","organSystem":"Blood and lymphatic system disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":269},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":138}]},{"term":"Device thrombus","organSystem":"General disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":16,"numAffected":15,"numAtRisk":269},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":138}]},{"term":"Epistaxis","organSystem":"Ear and labyrinth disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":5,"numAffected":5,"numAtRisk":269},{"groupId":"EG001","numEvents":2,"numAffected":1,"numAtRisk":138}]},{"term":"Gastrointestinal bleeding","organSystem":"Gastrointestinal disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":269},{"groupId":"EG001","numEvents":3,"numAffected":2,"numAtRisk":138}]},{"term":"Hematuria","organSystem":"Gastrointestinal disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":269},{"groupId":"EG001","numEvents":3,"numAffected":3,"numAtRisk":138}]},{"term":"Oral bleeding","organSystem":"General disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":269},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":138}]},{"term":"Other study related","organSystem":"General disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":269},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":138}]},{"term":"Pericardial effusion, non-serious","organSystem":"Cardiac disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":269},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":138}]},{"term":"Pseudoaneurysm","organSystem":"Vascular disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":269},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":138}]},{"term":"Rectal bleeding","organSystem":"Gastrointestinal disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":269},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":138}]},{"term":"Transient ischemic attack","organSystem":"Cardiac disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":269},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":138}]}]},"moreInfoModule":{"certainAgreement":{"piSponsorEmployee":false,"restrictiveAgreement":false},"pointOfContact":{"title":"WATCHMAN Trial Manager","organization":"Boston Scientific","phone":"1-800-227-3422"}}},"derivedSection":{"miscInfoModule":{"versionHolder":"2024-02-14"},"conditionBrowseModule":{"meshes":[{"id":"D000001281","term":"Atrial Fibrillation"}],"ancestors":[{"id":"D000002318","term":"Cardiovascular Diseases"},{"id":"D000001145","term":"Arrhythmias, Cardiac"},{"id":"D000006331","term":"Heart Diseases"},{"id":"D000010335","term":"Pathologic Processes"}],"browseLeaves":[{"id":"M21996","name":"Stroke","relevance":"LOW"},{"id":"M10233","name":"Ischemia","relevance":"LOW"},{"id":"M4276","name":"Atrial Fibrillation","asFound":"Atrial Fibrillation","relevance":"HIGH"},{"id":"M4143","name":"Arrhythmias, Cardiac","relevance":"LOW"},{"id":"M9109","name":"Heart Diseases","relevance":"LOW"}],"browseBranches":[{"abbrev":"BC10","name":"Nervous System Diseases"},{"abbrev":"BC14","name":"Heart and Blood Diseases"},{"abbrev":"All","name":"All Conditions"},{"abbrev":"BC23","name":"Symptoms and General Pathology"}]},"interventionBrowseModule":{"meshes":[{"id":"D000014859","term":"Warfarin"}],"ancestors":[{"id":"D000000925","term":"Anticoagulants"}],"browseLeaves":[{"id":"M4544","name":"Benzocaine","relevance":"LOW"},{"id":"M17292","name":"Warfarin","asFound":"Third","relevance":"HIGH"},{"id":"M3934","name":"Anticoagulants","relevance":"LOW"},{"id":"T433","name":"Tannic Acid","relevance":"LOW"}],"browseBranches":[{"abbrev":"CNSDep","name":"Central Nervous System Depressants"},{"abbrev":"All","name":"All Drugs and Chemicals"},{"abbrev":"AnCoag","name":"Anticoagulants"},{"abbrev":"Ot","name":"Other Dietary Supplements"}]}},"hasResults":true}